IMO VRT Share Price has bottomed out. There is significant room...

IMO VRT Share Price has bottomed out. There is significant room for growth over the next couple of years.

Some key highlights from the Annual Report and Financial Statements:

- Market leader in IVF industry with economies of scale and international presence/diversification
- Virtus Health Diagnostics 37% revenue growth PCP
- Genetic screening 33% revenue growth PCP
- Significant increase in OCF from $22m FY16 to $27M FY17 (22.7% growth - cash is king)
- International diversification and revenue streams in Ireland, Denmark and Singapore increasing significantly (Ireland soon to be EBITDA accretive, Singapore EBITDA accretive in second half FY17)
- VRT management have addressed under-performing VIC market and restructured management to improve performance
- Consistent dividend policy signalling positive expectations of future revenue growth
- 4.6% dividend yield
- P/E 14.0X

VRT looking very attractive on fundamentals.

IMO DYOR.